In the latest setback to Vical/Astellas partnership, lead CMV vaccine fails a pivotal PhIII study
When Vical’s lead vaccine flopped in a Phase II herpes study in 2016, the biotech and its partners at Astellas switched focus to a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.